KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Assets: 2010-2025

Historic Non-Current Assets for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2025 value amounting to $24.2 million.

  • TherapeuticsMD's Non-Current Assets fell 11.79% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 11.79%. This contributed to the annual value of $26.6 million for FY2024, which is 15.71% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Non-Current Assets is $24.2 million, which was down 3.49% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Non-Current Assets ranged from a high of $52.3 million in Q1 2021 and a low of $24.2 million during Q3 2025.
  • In the last 3 years, TherapeuticsMD's Non-Current Assets had a median value of $28.3 million in 2024 and averaged $29.2 million.
  • Data for TherapeuticsMD's Non-Current Assets shows a maximum YoY declined of 29.79% (in 2022) over the last 5 years.
  • TherapeuticsMD's Non-Current Assets (Quarterly) stood at $50.0 million in 2021, then declined by 29.79% to $35.1 million in 2022, then decreased by 10.24% to $31.5 million in 2023, then decreased by 15.71% to $26.6 million in 2024, then dropped by 11.79% to $24.2 million in 2025.
  • Its last three reported values are $24.2 million in Q3 2025, $25.0 million for Q2 2025, and $25.7 million during Q1 2025.